Trial Profile
Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Pregnenolone methyl ether (Primary)
- Indications Depressive disorders
- Focus Therapeutic Use
- Sponsors Mapreg
- 10 Nov 2022 Planned End Date changed from 1 Jun 2021 to 1 Dec 2023.
- 10 Nov 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Sep 2023.
- 04 Oct 2019 Planned End Date changed from 1 Sep 2020 to 1 Jun 2021.